To report a rare case of a collision tumor composed of an ACTH-secreting pituitary neuroendocrine tumor and a pituicytoma, detailing clinical presentation, radiological findings, and histopathological analysis, while emphasizing its significance in the context of existing literature.
Key Findings:
The patient had elevated cortisol and ACTH levels, confirming Cushing's disease.
Histopathological analysis revealed distinct characteristics of both the PitNET and pituicytoma, with Ki-67 indices indicating low proliferation rates.
Postoperative follow-up showed clinical and biochemical remission with no residual tumor.
Interpretation:
This case illustrates the rarity of collision tumors in the sellar region, particularly those involving an ACTH-secreting PitNET and pituicytoma, emphasizing the need for awareness, thorough diagnostic evaluation, and potential future research directions.
Limitations:
The rarity of collision tumors limits the generalizability of findings and their implications for clinical practice.
Long-term outcomes and recurrence rates for such tumors remain unclear due to limited case reports.
Conclusion:
The report underscores the importance of recognizing collision tumors to enhance diagnostic strategies and understanding of complex pituitary tumor biology, highlighting the need for interdisciplinary collaboration.
by Silvia Carolina Fernández, María Celina Bernhardt, Ezequiel Grondona, Carolina Leimgruber, Virginia Juárez, Ana Clara Venier, María Lorena Bertolino, Emilio Mezzano, Jorge Humberto Mukdsi, Favio Nicolás Pesaola, Ana Lucía De Paul
One of the most promising developments in advanced-stage Hodgkin lymphoma is the nivolumab-AVD regimen, which combines nivolumab with doxorubicin, vinblastine, and dacarbazine. This article provides practical knowledge for advanced practitioners to effectively manage the most common toxicities associated with nivolumab-AVD.
